Bristol-Myers Squibb (BMY) Competitors

$48.78
-0.21 (-0.43%)
(As of 12:04 PM ET)

BMY vs. ZTS, PFE, ABBV, MRK, JNJ, REGN, VRTX, GSK, SNY, and TAK

Should you be buying Bristol-Myers Squibb stock or one of its competitors? The main competitors of Bristol-Myers Squibb include Zoetis (ZTS), Pfizer (PFE), AbbVie (ABBV), Merck & Co., Inc. (MRK), Johnson & Johnson (JNJ), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), GSK (GSK), Sanofi (SNY), and Takeda Pharmaceutical (TAK). These companies are all part of the "pharmaceutical preparations" industry.

Bristol-Myers Squibb vs.

Bristol-Myers Squibb (NYSE:BMY) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, community ranking, institutional ownership and earnings.

Bristol-Myers Squibb presently has a consensus target price of $61.18, indicating a potential upside of 24.85%. Zoetis has a consensus target price of $218.00, indicating a potential upside of 45.76%. Given Zoetis' stronger consensus rating and higher possible upside, analysts clearly believe Zoetis is more favorable than Bristol-Myers Squibb.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bristol-Myers Squibb
1 Sell rating(s)
15 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.11
Zoetis
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00

Zoetis has a net margin of 27.43% compared to Bristol-Myers Squibb's net margin of 17.83%. Zoetis' return on equity of 51.25% beat Bristol-Myers Squibb's return on equity.

Company Net Margins Return on Equity Return on Assets
Bristol-Myers Squibb17.83% 50.95% 16.67%
Zoetis 27.43%51.25%17.58%

Bristol-Myers Squibb has higher revenue and earnings than Zoetis. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bristol-Myers Squibb$45.01B2.21$8.03B$3.8612.69
Zoetis$8.54B8.01$2.34B$5.0729.50

Bristol-Myers Squibb has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500.

Bristol-Myers Squibb received 183 more outperform votes than Zoetis when rated by MarketBeat users. However, 77.76% of users gave Zoetis an outperform vote while only 66.96% of users gave Bristol-Myers Squibb an outperform vote.

CompanyUnderperformOutperform
Bristol-Myers SquibbOutperform Votes
1078
66.96%
Underperform Votes
532
33.04%
ZoetisOutperform Votes
895
77.76%
Underperform Votes
256
22.24%

Bristol-Myers Squibb pays an annual dividend of $2.40 per share and has a dividend yield of 4.9%. Zoetis pays an annual dividend of $1.73 per share and has a dividend yield of 1.2%. Bristol-Myers Squibb pays out 62.2% of its earnings in the form of a dividend. Zoetis pays out 34.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

76.4% of Bristol-Myers Squibb shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 0.1% of Bristol-Myers Squibb shares are owned by company insiders. Comparatively, 0.2% of Zoetis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Bristol-Myers Squibb had 15 more articles in the media than Zoetis. MarketBeat recorded 41 mentions for Bristol-Myers Squibb and 26 mentions for Zoetis. Zoetis' average media sentiment score of 0.75 beat Bristol-Myers Squibb's score of 0.38 indicating that Zoetis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bristol-Myers Squibb
17 Very Positive mention(s)
4 Positive mention(s)
10 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Zoetis
15 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Zoetis beats Bristol-Myers Squibb on 15 of the 20 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BMY vs. The Competition

MetricBristol-Myers SquibbPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$99.59B$6.43B$4.79B$17.31B
Dividend Yield4.97%3.09%5.47%3.57%
P/E Ratio12.698.21190.2621.90
Price / Sales2.21300.612,317.2010.31
Price / Cash3.9319.2631.6314.98
Price / Book3.385.604.664.93
Net Income$8.03B$140.09M$102.16M$963.51M
7 Day Performance2.45%-0.08%0.41%2.52%
1 Month Performance-5.64%-8.38%-5.78%-1.85%
1 Year Performance-30.54%0.99%10.01%90.34%

Bristol-Myers Squibb Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZTS
Zoetis
4.8249 of 5 stars
$153.02
+2.2%
$221.75
+44.9%
-15.4%$69.99B$8.54B30.1814,100Analyst Report
PFE
Pfizer
4.995 of 5 stars
$25.69
-0.8%
$36.88
+43.5%
-34.5%$145.47B$58.50B71.3688,000Upcoming Earnings
ABBV
AbbVie
4.9364 of 5 stars
$162.54
+0.5%
$177.43
+9.2%
+4.4%$287.80B$54.32B59.5450,000Upcoming Earnings
MRK
Merck & Co., Inc.
4.8374 of 5 stars
$125.06
-0.9%
$131.25
+4.9%
+10.0%$316.78B$60.12B893.2972,000Upcoming Earnings
Analyst Revision
JNJ
Johnson & Johnson
4.9067 of 5 stars
$144.45
-2.1%
$177.31
+22.7%
-8.1%$348.09B$85.16B10.46131,900Options Volume
REGN
Regeneron Pharmaceuticals
3.7409 of 5 stars
$894.14
-0.5%
$970.57
+8.5%
+13.3%$98.14B$13.12B25.7313,450Analyst Revision
VRTX
Vertex Pharmaceuticals
4.363 of 5 stars
$394.17
-0.8%
$424.62
+7.7%
+22.3%$101.88B$9.87B28.385,400Analyst Revision
GSK
GSK
2.6808 of 5 stars
$39.95
-1.4%
N/A+12.3%$82.78B$37.71B13.2770,200Upcoming Earnings
Options Volume
News Coverage
SNY
Sanofi
3.0816 of 5 stars
$45.80
-1.0%
$55.00
+20.1%
-15.9%$115.86B$46.61B19.4186,088Upcoming Earnings
TAK
Takeda Pharmaceutical
0.2651 of 5 stars
$13.24
+0.5%
$14.00
+5.7%
-20.6%$41.90B$4.17T20.0649,095

Related Companies and Tools

This page (NYSE:BMY) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners